DE69132352T2 - Protein-antagonisten der blut-koagulation und ihre verwendung - Google Patents

Protein-antagonisten der blut-koagulation und ihre verwendung

Info

Publication number
DE69132352T2
DE69132352T2 DE69132352T DE69132352T DE69132352T2 DE 69132352 T2 DE69132352 T2 DE 69132352T2 DE 69132352 T DE69132352 T DE 69132352T DE 69132352 T DE69132352 T DE 69132352T DE 69132352 T2 DE69132352 T2 DE 69132352T2
Authority
DE
Germany
Prior art keywords
factor
viia
human factor
monoclonal antibody
factor viia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69132352T
Other languages
German (de)
English (en)
Other versions
DE69132352D1 (de
Inventor
K. Brunck
R. Soule
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Pharmaceuticals LLC
Original Assignee
Corvas International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvas International Inc filed Critical Corvas International Inc
Publication of DE69132352D1 publication Critical patent/DE69132352D1/de
Application granted granted Critical
Publication of DE69132352T2 publication Critical patent/DE69132352T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69132352T 1990-10-22 1991-10-17 Protein-antagonisten der blut-koagulation und ihre verwendung Expired - Fee Related DE69132352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60145490A 1990-10-22 1990-10-22
US07/759,443 US5506134A (en) 1990-10-22 1991-09-13 Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
PCT/US1991/007811 WO1992006711A1 (en) 1990-10-22 1991-10-17 Blood coagulation protein antagonists and uses therefor

Publications (2)

Publication Number Publication Date
DE69132352D1 DE69132352D1 (de) 2000-09-07
DE69132352T2 true DE69132352T2 (de) 2001-03-15

Family

ID=27083860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69132352T Expired - Fee Related DE69132352T2 (de) 1990-10-22 1991-10-17 Protein-antagonisten der blut-koagulation und ihre verwendung

Country Status (9)

Country Link
US (1) US5506134A (https=)
EP (1) EP0554383B1 (https=)
JP (1) JP2680192B2 (https=)
AT (1) ATE195149T1 (https=)
AU (1) AU654311B2 (https=)
CA (1) CA2094372A1 (https=)
DE (1) DE69132352T2 (https=)
ES (1) ES2151880T3 (https=)
WO (1) WO1992006711A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
CA2180140A1 (en) * 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PL362320A1 (en) 2000-12-06 2004-10-18 Aventis Pharma Deutschland Gmbh Guanidine and amidine derivatives as factor xa inhibitors
EP1348443A4 (en) * 2000-12-08 2005-07-06 Takeda Pharmaceutical COMBINED MEDICINES
WO2002059268A2 (en) * 2001-01-23 2002-08-01 Saint Louis University Factor ixa: factor viiia interaction and methods therefor
EP1260817A3 (en) 2001-05-08 2002-12-18 Warner-Lambert Company Method for direct measurement of coagulation factor VIIa activity in plasma
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
JP4584574B2 (ja) * 2001-07-03 2010-11-24 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 第ＶＩＩａ因子−アンチトロンビン複合体を測定するためのアッセイ
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US20040126856A1 (en) * 2002-01-23 2004-07-01 Bajaj Paul S. Factor ixa: factor Vllla interaction and methods therefor
AP2004003113A0 (en) * 2002-02-22 2004-09-30 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US6706068B2 (en) 2002-04-23 2004-03-16 Bret A. Ferree Artificial disc replacements with natural kinematics
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
WO2005001080A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006071794A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
DE10333508A1 (de) * 2003-07-18 2005-02-17 Technische Universität Dresden Gegen Prothrombin gerichtete Erkennungsmoleküle und die Verwendung dieser
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US20070207154A1 (en) * 2004-04-16 2007-09-06 Martin Friedlander Method of modulating vascularization
TR201820051T4 (tr) * 2008-06-19 2019-01-21 Prothix Bv Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
ES2984405T3 (es) 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
PH12021552586A1 (en) 2019-04-17 2023-07-31 Novo Nordisk As Bispecific antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
SE461315B (sv) * 1988-06-16 1990-02-05 Jan Niels Faergemann Anvaendning av en komposition innehaallande aluminiumacetotartrat och en diol foer att minska hudirritationer orsakade av urin eller avfoering, samt bloeja impregnerad med kompositionen
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides

Also Published As

Publication number Publication date
DE69132352D1 (de) 2000-09-07
JPH06502307A (ja) 1994-03-17
JP2680192B2 (ja) 1997-11-19
AU9029891A (en) 1992-05-20
WO1992006711A1 (en) 1992-04-30
ATE195149T1 (de) 2000-08-15
ES2151880T3 (es) 2001-01-16
CA2094372A1 (en) 1992-04-23
EP0554383A1 (en) 1993-08-11
US5506134A (en) 1996-04-09
EP0554383A4 (https=) 1994-04-27
EP0554383B1 (en) 2000-08-02
AU654311B2 (en) 1994-11-03

Similar Documents

Publication Publication Date Title
DE69132352T2 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
US6221659B1 (en) Blood coagulation protein antagonists and uses therefor
US5990079A (en) Agents affecting thrombosis and hemostasis
DE69736197T2 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DE69121272T2 (de) Bispezifische monoklonale Antikörper, ihre Produktion und Verwendung
DE69530316T2 (de) Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
DE69229911T2 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen
DE68919361T2 (de) Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
DE68924773T2 (de) Monoklonale antikörper gegen den bereich der leichten kette von menschlichem faktor xii sowie methoden zu deren herstellung und verwendung.
JPWO1996017078A1 (ja) 抗血栓剤及び抗フォンビルブランド因子モノクローナル抗体
DE60033814T2 (de) Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers
UA116531C2 (uk) Виділена молекула антитіла, яка специфічно зв'язується з ділянкою екзосайта 1 тромбіну, та її застосування
DE69411898T2 (de) Neue antikoagulant-cofaktor aktivität
DE69435072T2 (de) Antikörper gegen menschliches lösliches fibrin, hybridome, die sie produzieren und immunmessverfahren
DE69011531T2 (de) Von faktor vii abgeleitete peptide mit antihämostatischer wirkung.
KR20030034071A (ko) 항혈전제
DE69229948T2 (de) hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN
DE3687542T2 (de) Monoklonaler antikoerper gegen humanes protein c.
EP0457532A1 (en) Monoclonal antibody which inhibits the biological action of platelet factor 4
Arnout et al. Thrombosis: fundamental and clinical aspects
US20040072757A1 (en) Agents affecting thrombosis and hemostasis
AT404554B (de) Pharmazeutische präparation
Meyer Monoclonal Antibodies to Human von Willebrand Factor Study of its Structure-Function Relationship
MEYER glycoprotein is present in plasma at about 5-10 ug per ml as a set

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee